BRAINSTORM CELL THERAPEUTICS INC.

BCLI · OTC · SIC 2836: Biological Products, (No Diagnostic Substances)
382
SEC Filings

Business Summary

Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative diseases including ALS, progressive multiple sclerosis, and Alzheimer's disease. Its proprietary NurOwn platform induces bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammation, and promote neuronal survival. NurOwn has completed Phase 3 ALS and Phase 2 PMS trials and received FDA SPA agreement for a planned Phase 3b ALS trial.

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBCLIdiscussed_in_filing Trusted Computing
topic_mentionBCLIdiscussed_in_filing Blockchain & Crypto
topic_mentionBCLIdiscussed_in_filing Regulation
topic_mentionBCLIdiscussed_in_filing Healthcare & Bio
topic_mentionBCLIdiscussed_in_filing Platform & Ecosystem
topic_mentionBCLIdiscussed_in_filing Trusted Computing
topic_mentionBCLIdiscussed_in_filing Blockchain & Crypto
topic_mentionBCLIdiscussed_in_filing Regulation
topic_mentionBCLIdiscussed_in_filing Healthcare & Bio
topic_mentionBCLIdiscussed_in_filing Platform & Ecosystem
topic_mentionBCLIdiscussed_in_filing Trusted Computing
topic_mentionBCLIdiscussed_in_filing Blockchain & Crypto
topic_mentionBCLIdiscussed_in_filing Regulation
topic_mentionBCLIdiscussed_in_filing Healthcare & Bio
topic_mentionBCLIdiscussed_in_filing Platform & Ecosystem
topic_mentionBCLIdiscussed_in_filing Trusted Computing
topic_mentionBCLIdiscussed_in_filing Blockchain & Crypto
topic_mentionBCLIdiscussed_in_filing Regulation
topic_mentionBCLIdiscussed_in_filing Healthcare & Bio
topic_mentionBCLIdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001104659-26-037927EDGAR94K words
2025-03-312024-12-310001410578-25-000545EDGAR—
2024-04-012023-12-310001410578-24-000385EDGAR—
2023-03-302022-12-310001410578-23-000426EDGAR—
2022-03-282021-12-310001410578-22-000554EDGAR—
2021-02-042020-12-310001104659-21-011928EDGAR—
2020-02-182019-12-310001104659-20-022244EDGAR—
2019-03-292018-12-310001144204-19-017041EDGAR—
2018-03-082017-12-310001144204-18-013470EDGAR—
2017-03-292016-12-310001144204-17-017265EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001104659-25-112701EDGAR27K words
2025-08-142025-06-300001410578-25-001782EDGAR—
2025-05-152025-03-310001410578-25-001347EDGAR—
2024-11-142024-09-300001410578-24-002000EDGAR—
2024-08-142024-06-300001410578-24-001400EDGAR—
2024-05-142024-03-310001410578-24-000820EDGAR—
2023-11-142023-09-300001410578-23-002443EDGAR—
2023-08-142023-06-300001410578-23-001831EDGAR—
2023-05-152023-03-310001410578-23-001157EDGAR—
2022-11-142022-09-300001410578-22-003271EDGAR—
2022-08-152022-06-300001410578-22-002510EDGAR—
2022-05-162022-03-310001410578-22-001572EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001104659-26-037760EDGAR3K words
2026-02-270001104659-26-021613EDGAR—
2026-02-130001104659-26-015262EDGAR—
2026-01-090001104659-26-002494EDGAR—
2025-11-140001104659-25-112682EDGAR—
2025-11-060001104659-25-107833EDGAR—
2025-08-140001104659-25-078116EDGAR—
2025-07-170001104659-25-068709EDGAR—
2025-06-250001104659-25-062595EDGAR—
2025-06-160001104659-25-059900EDGAR—

382 total filings indexed. 350 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

amyotrophic-lateral-sclerosis-(als) progressive-multiple-sclerosis-(pms) alzheimer's-disease neurodegenerative-diseases current-good-manufacturing-practice-(cgmp) fda-fast-track-designation fda-orphan-drug-status ema-orphan-drug-status

Company Identity

CIK0001137883
TickerBCLI
ExchangeOTC
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
HeadquartersUnited States (specific city not mentioned); R&D center in Petach Tikva, Israel

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 39af83bba65445460e884061119590ab30789976786ec6ca1bfc8eee3dc9bcde
parent: ce811a09eecd02f7b60a74bac6bd018df93693e07a2c9f9351bc46f11f11dd8f
content hash: e4af65b94ce3780cf834e87148c2824a9a2b2347876de02f5b38a8a254d03d36
signed: 2026-04-13T04:43:54.218Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf